In Phase A, participants will obtain distinct doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Extra members will be enrolled with the determined monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 is going to be specified as "include-on" therapy. In Segment https://leonardow000ite3.wikisona.com/user